Epizyme (EPZM +2.4%) trades higher after Wedbush's Greg Wade ramps up coverage with an...

|About: Epizyme (EPZM)|By:, SA News Editor

Epizyme (EPZM +2.4%) trades higher after Wedbush's Greg Wade ramps up coverage with an Outperform rating and a $37 price target. Wade says that advances in genetically defining sub-sets of cancer patients have led to identifying certain histone methyltransferase proteins as key malignant drivers, and EPZM's small molecule drug discovery platform is key to marrying these antagonists with the genetically definable malignancy.